Business Wire

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping

30.3.2026 11:00:00 CEST | Business Wire | Press Release

Share

The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/

Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London

Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport.

Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders.

World-class, immersive events will unfold across fourteen iconic international venues, spanning Europe, North America, and the Middle East inviting fans closer than ever to the grit, beauty, and power of high-stakes jumping.

The inaugural season will run from March to October 2027.

Designed to open the sport to new audiences whilst respecting its heritage, the PJL combines extraordinary athletic performance with premium entertainment, strengthened by the league’s partnership with Emmy award-winning production company Box to Box Films, and supported by a free-to-view broadcasting model. Cutting-edge technology, radical transparency, and innovative team formats enhance the drama, intensity, and rivalry that defines elite sport – unlocking the full potential of jumping, demanded by today’s global sports and entertainment marketplace, without compromising its core values.

With exceptional welfare standards, a pioneering development pathway, and financial sustainability at its core, the PJL is professionalising jumping.

This is elite sport.

This is extraordinary skill.

This is our sport as you’ve always loved it.

This is our sport as you’ve never seen it.

This is the PJL - the future of jumping.

Frank McCourt, Founder and Chairman of the PJL: “For far too long, many of the world’s best riders have been forced to choose between pursuing their talent and passion and building a sustainable career. The PJL is changing that by creating a clear and viable path for athletes to earn a great living by competing at the highest level, without compromising the traditions and values that define jumping. By aligning opportunity with performance and commitment, we are reshaping the future of the sport and empowering its most talented athletes to devote themselves fully to excellence.”

Neil Moffitt, Chief Executive Officer: “Today marks a major milestone for equestrian sport. The PJL has assembled an exceptional operations team to deliver on our mission to bring a new level of energy, excitement, and engagement to the sport.”

Lisa Lazarus, Chief Equestrian Advisor: “There is no greatness in horse sport without the welfare and safety of the horse. The PJL’s competition design, scheduling, travel approach, and veterinary oversight will reflect uncompromising standards of care, rest, and responsible decision-making every step of the way.”

Laura Kraut, Olympic gold medal-winning rider:“An Olympic gold medal is the greatest thing you can achieve in the sport. Yet for jumping athletes like me, the commercial opportunities often don’t follow. The gap between what athletes achieve and what they’re able to build tells you everything about the sport’s limited infrastructure to convert elite achievement into recognition and reward. I welcome the PJL’s values to reform this model in a way that drives revenue opportunities for all involved.”

Scott Brash, Olympic gold medal winner & current World Number 1 rider:With horses—and in our sport especially—learning never stops. One of my biggest goals is to help move the sport forward, creating a better environment for athletes, horses, everyone involved, and those who follow along. I believe the PJL gives us a meaningful platform to have these important conversations. Competing at the highest level comes with enormous costs, and for most riders, securing financial support while dedicating the necessary time to the sport is a constant balancing act.

What makes the PJL so impactful is that it rewards riders in a way that allows us to truly prioritize both our own well-being and that of our horses—making full-time training and proper rest possible. That’s something genuinely groundbreaking.”

About the Premier Jumping League (PJL)

The PJL is a new global showjumping competition redefining the sport through elite team competition, record-breaking prize money, and a sustainable professional model for riders. Backed by McCourt Global and shaped by leaders from equestrian sport, international competition, and entertainment, the PJL brings together the world’s top riders and horses to compete across fourteen iconic venues in Europe, North America, and the Middle East. With sixteen teams, an innovative rider selection process and a guaranteed $300 million prize pot, the PJL combines world-class athletic performance with premium entertainment, opening the sport to new global audiences while honouring its heritage.

About McCourt Global

McCourt Global is a diversified enterprise building for tomorrow across real estate and infrastructure, sports, technology, and media. With a global portfolio, the company combines operational expertise with strategic capital to develop impactful projects that create long-term economic and social value. Founded by Executive Chairman Frank McCourt, a civic entrepreneur and fifth-generation builder, and led by an international executive team, McCourt Global builds on a 133-year legacy of developing infrastructure and delivering strong financial results alongside a commitment to social impact—an approach that began with the McCourt family’s original company in Boston in 1893.

McCourt Global’s portfolio includes McCourt Partners, the real estate and infrastructure firm; Olympique de Marseille, the iconic Ligue 1 football club; the Premier Jumping League, a global showjumping competition redefining the sport; and Project Liberty, an initiative to build a better internet where individuals have greater control over their data in the era of AI. Headquartered in New York, McCourt Global operates across North America, Europe, and beyond. For more information, visit McCourt Global’s website or follow the company on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260330990938/en/

Contacts

The PJL: Kelly Hogarth | pressoffice@pjl.com - press@pjl.com​

McCourt Global: Anna Feagan | anna.feagan@mccourt.com

Follow the PJL today:
Website: www.pjl.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.pjl.com&esh
eet=54468060&newsitemid=20260330990938&lan=en-US&anchor=www.pjl.com&index=7&md5=
73b90762776f0772a1751cec3624e334
Substack: @thepjl
Instagram: @the_pjl_official

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press Release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press Release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press Release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press Release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press Release

The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye